anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hematopoietic stem cell transplantation is a common life-saving treatment for hematologic malignancies, though can lead to long-term functional impairment, fatigue, muscle atrophy, with decreased quality of life. Although traditional exercise has helped reduce these effects, it is inconsistently recommended and infrequently maintained, and most patients remain sedentary during and after treatment. There is need for alternative rehabilitation strategies, like neuromuscular electrical stimulation, that may be more amenable to the capabilities of hematopoietic stem cell transplant recipients. Patients receiving autologous HCT are being enroled in a randomized controlled trial with 1:1 (neuromuscular electrical stimulation:sham) design stratified by diagnosis and sex. Physical function, body composition, quality of life, and fatigue are assessed prior to hematopoietic stem cell transplant (prior to initiating preparatory treatment) and 24±5 days post hematopoietic stem cell transplant (Follow-up 1); physical function and quality of life are also assessed 6-months post hematopoietic stem cell transplant (Follow-up 2). The primary outcome is between-group difference in the 6-minute walk test change scores (Follow-up 1-Pre-transplant; final enrolment goal N = 23/group). We hypothesize that 1) neuromuscular electrical stimulation will attenuate hematopoietic stem cell transplant-induced adverse effects on physical function, muscle mass, quality of life, and fatigue compared to sham at Follow-up 1, and 2) Pre-transplant physical function will significantly predict fatigue and quality of life at Follow-up 2. We will also describe feasibility and acceptability of neuromuscular electrical stimulation during hematopoietic stem cell transplant. This proposal will improve rehabilitative patient care and quality of life by determining efficacy and feasibility of a currently underutilized therapeutic strategy aimed at maintaining daily function and reducing the impact of a potent and widely used cancer treatment. This trial is registered with clinicaltrials.gov (NCT04364256).
Participants will receive once-weekly s.c. injection of semaglutide in 20 week dose escalation period with dose escalation (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week until maintenance dose of 2.4 mg of semaglutide was reached. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 72.
The invention concerns fusion proteins, wherein two endoglycosidases are fused, possibly via a linker. The fusion enzymes according to the invention have structure (1): EndoX-(L) p -EndoY (1), wherein EndoX is an endoglycosidase, EndoY is an endoglycosidase distinct from EndoX, L is a linker and p is 0 or 1. Such fusion enzymes capable of trimming glycoproteins comprising at least two distinct glycoforms in a single step. The invention further concerns the use of the fusion enzyme according to the invention for trimming glycoproteins. In another aspect, the invention relates to the process of production of the fusion enzyme. In a further aspect, the inventions concerns a process for trimming glycoproteins, comprising trimming the glycoprotein with a fusion enzyme according to the invention, to obtain a trimmed glycoprotein.
PURPOSE:To make it possible to satisfy various conditions such as simplicity, high sensitivity, stability and low cost etc., by contacting a liquid medium with a U-shape or V-shape microplate (MP), to which the specific bonding homologue of a ligand was bonded, for a predetermined time. CONSTITUTION:A liquid medium is contacted with a U-shape or V-shape MP, to which the specific bonding homologue of a ligand was bonded, for a predetermined time. After washing, a carrier particle, to which the ligand or the specific bonding analogue thereof was bonded, is contacted with MP for a predetermined time and the agglutination image on the bottom part of MP is subsequently observed. Because the bottom part of MP is inclined in a U-shape or V-shape, when reaction is negative, the carrier particle is fallen to the center of the bottom part according to gravity to show a button shaped agglutination image. When reaction is positive, the carrier particle is adhered to the inclined surface of MP without being fallen to the bottom part to show a diffused agglutination image. Therefore, by observing the agglutination image, it can be judged whether reaction is positive or negative and various conditions such as simplicity, stability and low cost etc. can be satisfied.
PROBLEM TO BE SOLVED: To prepare a makeup cosmetic, excluding for lip use, having high water retentivity, emolument property, stability and skin safety by mixing an oily agent of a specific condensation product in the cosmetic. SOLUTION: This cosmetic is prepared by mixing an oily agent, a condensation product of a diglycerine ester with a branched 16-18C monocarboxylic acid (isopalmitic acid and isostearic acid are especially preferable) and a 6-10C dicarboxylic acid (e.g. sebasic acid etc.). The example of the oily agent is a condensation product such as of diglyceryl isopalmitate with sebasic acid and diglyceryl isostearate with sebasic acid. This oil is mixed in an amount of 2.0-50.0wt.%. This oily agent has both water retentivity and emolument property and further has functions of an emulsifier and a dispersion auxiliary.
PURPOSE:To obtain a hair growing agent excellent in hair-growing effect and having high safety and to obtain a cosmetic for the hair containing the hair growing agent and capable of continuously and safely using for a long period. CONSTITUTION:This hair growing agent consists of a compound of formula I (R1 is a short-chain length alkyloxycarbonyl, a short-chain length alkyl or a hydroxycarbonylalkyl; R2 and R3 are each H or a short chain length alkyloxy), e.g. 1-methoxycarbonyl-beta-carboline of formula II, a 1-ethyl-4,8-dimethoxy-beta- carboline of formula III or a beta-carboline-1-propionic acid of formula IV. This hair growing agent is blended in an amount of 0.01-10wt.% in the cosmetic for the hair so as to provide trichogenous effect. The compound of formula I is obtained by extracting Peucedain praeruptorum Dunn, pref. its radix, which is a plant of Umbelliferae or its root respectively, using a polar solvent.
Determination of serum transaminases (SGOT, SGPT) should be made prior to initiation of therapy and should be monitored monthly. If serum transaminases become elevated during therapy, ethionamide and the companion anti-tuberculosis drug or drugs may be discontinued temporarily until the laboratory abnormalities have resolved. Ethionamide and the companion anti-tuberculosis medication(s) then should be reintroduced sequentially to determine which drug (or drugs) is (are) responsible for the hepatotoxicity.

Blood glucose determinations should be made prior to and periodically throughout therapy with Trecator. Diabetic patients should be particularly alert for episodes of hypoglycemia.

Periodic monitoring of thyroid function tests is recommended as hypothyroidism, with or without goiter, has been reported with ethionamide therapy.
OBJECTIVE: To determine whether polymorphisms of the IL10 and IL17 genes are associated with severe asthma control and bronchodilator reversibility in children and adolescents with severe asthma.
METHODS: This was a cross-sectional study, nested within a prospective cohort study of patients with severe asthma. Two outcomes were evaluated: asthma control and bronchodilator reversibility. We extracted DNA from peripheral blood and genotyped three single nucleotide polymorphisms: rs3819024 and rs2275913 in the IL17A gene; and rs3024498 in the IL10 gene. For the association analyses, we performed logistic regression in three genetic models (allelic, additive, and dominant).
RESULTS: The rs3024498 C allele in the IL10 gene was associated with failure to achieve asthma control despite regular treatment (p = 0.02). However, the G allele of the IL17A rs3819024 polymorphism was associated with failure to respond to stimulation with a b2 agonist. The rs2275913 polymorphism of the IL17A gene showed no relationship with asthma control or bronchodilator reversibility.
CONCLUSIONS: In pediatric patients with severe asthma, the IL10 polymorphism appears to be associated with failure to achieve clinical control, whereas the IL17A polymorphism appears to be associated with a worse bronchodilator response. Knowledge of the involvement of these polymorphisms opens future directions for pharmacogenetic studies and for the implementation of individualized therapeutic management of severe asthma in pediatric patients.
Methods and devices are disclosed for managing a resource of a communication device configured to process and communicate medical data in addition to other data. The systems and devices may implement the method, including determining whether to switch to a medical mode based on at least one signal. In response to determining to switch to the medical mode, the communication device may be switched to the medical mode. A resource status associated with a plurality of resources used by the communication device may be weighed against a medical data criticality associated with the medical data managed by the communication device. The method may include allocating a resource of the plurality of resources on a sliding priority scale. The allocating may include allocating a resource of the plurality of resources preferentially to the medical data over the other data.
PURPOSE: To perform a systematic review to compare clinical outcomes, complications, and reoperation rates of patients undergoing the Latarjet procedure with screw vs suture-button fixation.
METHODS: A systematic review was performed by searching PubMed, the Cochrane Library, and Embase to identify clinical studies directly comparing screw vs suture-button fixation for the Latarjet procedure. The search terms used were shoulder screw suture button. Patients were evaluated based on reoperation rate, complication rate, recurrent instability, radiologic outcomes, and patient-reported outcomes. Graft and screw position were assessed via computed tomography.
RESULTS: Seven studies (1 Level II, 6 Level III) met inclusion criteria, with 845 patients undergoing the Latarjet procedure with screw fixation (screw group) and 279 patients with suture-button fixation (suture-button group). Mean patient age ranged from 21.2 to 29.6 years. Mean follow-up time ranged from 6.0 to 40.8 months. The recurrent instability rate ranged from 0% to 2.5% in the screw group and 0% to 8.3% in the suture-button group. The reoperation rate ranged from 0% to 7.7% in the screw group compared to 0% to 1.9% in the suture-button group. One study reported significantly lower visual analog scale pain scores in the suture-button group compared with the screw group (1.5 vs 1.2, P = .003). No other studies reported significant differences in any patient-reported outcomes. There was no significant difference in horizontal or vertical graft position, graft union rate, or complication rate between groups in any study.
CONCLUSIONS: The Latarjet procedure with screw fixation may result in a lower risk of recurrent instability compared to suture-button fixation, although screw fixation may also have a higher reoperation rate due to hardware-related complications.
LEVEL OF EVIDENCE: Level III, systematic review of Level II to III studies.
PCT No. PCT/JP87/00021 Sec. 371 Date Aug. 31, 1987 Sec. 102(e) Date Aug. 31, 1987 PCT Filed Jan. 14, 1987 PCT Pub. No. WO87/04434 PCT Pub. Date Jul. 30, 1987.This invention provides an indenothiazole derivative and a process for manufacturing the same. The said indenothiazole derivative is represented by the following formula: <IMAGE> (Ia)  wherein X and Y are identical with, or different from, each other and are each a hydrogen atom, halogen atom, low alkyl group or low alkoxy group; n is an integer of from 0 to 4; R1 is a hydrogen atom, low alkyl group, unsubstituted or substituted phenyl group; R2 is a low alkyl group, cycloalkyl group, low alkoxyl group, unsubstituted or substituted phenoxy group, unsubstituted or substituted phenyl group, alkenyl group, heterocyclic group or cycloamino group; R3 is a hydrogen atom, low alkyl group or acyl group; and R2 and R3 may be combined to form a cycloamino group. Further, this invention also provides a tautomer of the compound represented by the above formula (Ia), wherein all the symbols are as defined above except that R3 is limited to a hydrogen atom.
Purified collagen is produced by a method containing steps of contacting a collagen sample with a first proteolytic enzyme followed by contacting with a reducing agent and a second proteolytic enzyme. Preferably, the first and second proteolytic enzymes are papain and the reducing agent is sodium sulfide, dithiothreitol, glutathionine or sodium borohydride. A biocompatible collagen is prepared by contacting the purified collagen with a delipidation agent such as chloroform or methanol to produce delipidated collagen, and then contacting the delipidated collagen with a phosphorylation agent such as sodium trimetaphosphate. Prior to phosphorylation, the delipidated collagen may be treated by compressing, dehydrating, dispersing and drying to form collagen fibers. Also, prior to phosphorylation, the delipidated collagen may be treated by filter-sterilizing. De-epithelializing of the collagen may carried out prior to treating with the first proteolytic enzyme. The purified and biocompatible collagen may be used in transplantation or hemostasis, and may be provided with compounds such as antimicrobials, antivirals, growth factors and other compounds suitable for biomedical use.
Fifty children aged 4 to 6 years old with active dentin caries lesions (score 5 according to International Detection and Assessment System (ICDAS II) criteria) will be enrolled in the study. They will be equally and randomly allocated into 2 groups: a group receiving NSF and a control group receiving SDF treatment. Microbiological samples will be collected from the carious lesions and from unstimulated saliva at the baseline and at the 1 and 3 months' follow-up appointments. Bacterial counts will be assessed using Mitis Salivarius agar (selective culture media for S. mutans) and Rogosa agar (selective culture media for lactobacilli), and the results will be expressed in colony-forming units. Data regarding the children's oral health will be collected and their dmf index will be scored. The arrest of active carious lesions will be measured at the follow-up appointments according to ICDAS II criteria.
An apparatus is provided. The apparatus includes a memory, a second type spectrum measurer, and a processor. The memory stores an individualized blood sugar estimation model. The second type spectrum measurer measures second type spectrum data for a skin of a user. The processor calculates blood sugar of the user based on the measured second type spectrum data and the individualized blood sugar model. The blood sugar model is generated based on blood sugar profile data of the user calculated based on a first type spectrum-blood sugar profile relationship model and training second type spectrum data for the skin of the user.
Group B (n=14) will undergo Muscle Energy Technique without stationary cycling. In the first 3 days, an initial assessment, including Visual Gait Analysis, Observational Gait Scale, and Foot Posture Index, will be conducted. From Week 1 to 4, the technique involves the patient contracting for 5-10 seconds while the therapist resists, followed by a rapid 10-second stretch (3-5 repetitions). A follow-up assessment will occur in Week 4. From Week 5 to 8, the same process continues with 5-8 repetitions, ending with a final assessment in Week 8.
The intervention consisted of providing nutritional supplements and supervised exercise for 12 weeks. After the intervention (the 12th week), the trial commissioned company provides nutritional supplements with a market price of about NT$4,000 per month for three months free to participants who are willing to continue taking the products. Those participants will be tracked for one year.
When plants are transferred from nursery to urban environments, they often face drought stress due to inadequate maintenance, such as insufficient irrigation. Using drought tolerant species may help mitigate the adverse impact of drought stress in urban settings. Additionally, utilizing novel technologies for water status monitoring may help optimize irrigation schedules to prevent transplanting failures. This study investigated the physiological and biochemical responses of two ornamental shrubs, Photinia x fraseri and Viburnum tinus, subjected to water stress of increasing severity and rewatering. Water relations, gas exchanges, chlorophyll fluorescence and biochemical analyses were conducted alongside real-time monitoring of water status using leaf-water-meter sensors (LWM). The progression of water stress had a notable negative impact on leaf gas exchanges and water relations in both species. Notably, P. fraseri avoided photoinhibition by reducing chlorophyll content and actual efficiency of PSII. Adjustments in leaf phenolic compounds played a significant role in enhancing drought tolerance of both species due to their antioxidant and photoprotective properties. Upon rewatering, both species exhibited complete recovery in their physiological functions, underscoring their remarkable tolerance and resilience to drought stress. Additionally, LWM sensors efficiently tracked the dehydration levels, exhibiting a rising trend during the water stress progression and a subsequent decline after rewatering for both species. These findings confirm the reliability of LWM sensors in monitoring physiological status of plants in outdoor contexts, making them a suitable tool for use in urban settings.
BACKGROUND: There are many consequences of lower limb amputation, including altered biomechanics of gait. It has previously been shown that these can lead to increased rates of osteoarthritis (OA). A common and successful treatment for severe OA is joint replacement. However, it is unclear whether amputees undergoing this surgery can expect the same outcomes or complication profile compared with non-amputees. Furthermore, there are key technical challenges associated with hip or knee replacement in lower limb amputees. This scoping review aimed to identify and summarise the existing evidence base.
METHODS: This was a systematic scoping review performed according to PRISMA guidelines. An electronic database search of MEDLINE (PubMed), Cochrane Library, EMBASE and CINAHL was completed from the date of inception to 1st April 2023. All peer reviewed literature related to hip or knee replacement among lower limb amputees was included.
RESULTS: Of the 931 records identified, 40 studies were included in this study. The available literature consisted primarily of case reports and case series, with generally low level of evidence. In total, there were 265 patients of which 195 received total hip replacement (THR), 51 received total knee replacement (TKR) and 21 received hip hemiarthroplasty. The most common reason for amputation was trauma (34.2%), and the main indication for joint replacement was OA (77.1%), occurring more frequently in the contralateral limb (66.7%). The outcomes reported varied widely between studies, with most suggesting good functional status post-operatively. A variety of technical tips were reported, primarily concerned with intra-operative control of the residual limb.
CONCLUSION: There is a need for more observational studies to clearly define the association between amputation and subsequent need for joint replacement. Furthermore, comparative studies are needed to identify whether amputees can be expected to achieve similar functional outcomes after surgery, and if they are at higher risk of certain complications.
OLINVYK can be administered by a healthcare provider with an initial dose of 1.5 mg. For PCA, the initial dose can be followed by access to patient demand doses with a 6-minute lock-out. The recommended demand dose is 0.35 mg. A demand dose of 0.5 mg may be considered for some patients if the potential benefit outweighs the risks. Supplemental doses of 0.75 mg OLINVYK can be administered by healthcare providers, beginning 1 hour after the initial dose, and hourly thereafter as needed.

Onset of analgesic effect is expected within 2 to 5 minutes after the initial dose [see Clinical Pharmacology (12.2)].

Do not administer single doses greater than 3 mg [see Adverse Reactions (6.1)].

The cumulative total daily dose should not exceed 27 mg. If patients reach a 27 mg cumulative daily dose and analgesia is still required, an alternative analgesic regimen should be administered until OLINVYK can be resumed the next day. Alternative analgesia may include multi-modal therapies. The safety of OLINVYK beyond 48 hours of use was not evaluated in controlled clinical trials [see Warnings and Precautions (5.5)].

Conversion Between Morphine Intravenous Injection and OLINVYK Intravenous Injection

Based on data collected in clinical studies, an initial 1 mg dose of OLINVYK is approximately equipotent to morphine 5 mg [see Clinical Pharmacology (12.2)]. As individual patients differ in their response to opioid drugs, this comparison should be used only as a guide.
This randomized, controlled trial tested the effectiveness of a nurse-run, telephone-based intervention to improve lipid control in patients with diabetes. Our patient population is predominantly low-income and Latino. Using our diabetes registry, we randomly assigned 381 patients to continue with their usual care and 381 to participate in our nurse run program. Three registered nurses learned algorithms for diabetes care. These algorithms address management of lipids, glycemic control, blood pressure, nephropathy, aspirin use, eye screening, pneumovax and influenza vaccines, obesity, and cigarette smoking. The nurses were also trained in motivational interviewing techniques and facilitation of patient self-management. The primary goal was to improve lipid control in our diabetic population. Secondary outcomes address blood pressure control, glycemic control, renal function, and medication adherence. In addition, a cost-effective analysis is being performed.
Acute pain after a surgical procedure may occur secondary to trauma from the procedure itself or from procedure-related complications. Appropriate peri-operative acute pain management is an important phase of patient's recovery since it's under-treatment can lead to adverse outcomes such as: thromboembolic and pulmonary complications, additional time spent in an intensive care unit or hospital, hospital readmission for further pain management, needless suffering, impairment of health-related quality of life, and development of chronic pain. Furthermore, it's over-treatment with opioid medications is associated with an increased risk of thromboembolic, infectious and gastrointestinal complications as well as increased length of hospital stay, cost of care and risk of opioid addiction.

Perioperative administration of intravenous (IV) non steroidal anti-inflammatory drugs (NSAID), such as ketorolac, has been shown to effectively decrease opioid requirements and pain levels while demonstrating tolerable side effects. Its use after total knee replacement has been associated with a 27% decrease in the use of morphine. When NSAID is combined with acetaminophen 1000mg every six hours, an additional benefit in terms of improved pain scores on post-operative day three was shown in patients who underwent total hip or knee arthroplasty. Therefore, the purpose of this study is to provide an effective alternative for pain management in Hispanic patients who underwent total knee replacement and evaluate the role of ketorolac and acetaminophen.